Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir Add-on Therapy in Newly Diagnosed Glioblastoma
2023-504846-73-01Phase 2Authorised
- Sponsor
- Karolinska Institutet
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Valganciclovir arm with Placebo arm (2 arms). Primary endpoint: Median overall survival. Planned start Oct 2024; status: authorised.
02
Drugs
valganciclovir
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-504846-73-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504846-73-01.